BRIEF-SQZ Biotechnologies Presents New EAPC Preclinical Data
* SQZ BIOTECHNOLOGIES PRESENTS NEW EAPC PRECLINICAL DATA DEMONSTRATING THAT MULTIPLEXED MRNA ENGINEERING OF IMMUNE CELLS INCREASES KILLER T CELL ACTIVITY IN VIVO Source text for Eikon: Further company coverage: